ArticleInflammopharmacology2026
Network pharmacology and in vivo experimental analysis for validating the antifibrotic potential of Punica granatum leaves against skin scleroderma: the role of oxidative stress, inflammation and TGF-β1/Snail 1/p-Smad 3 signaling pathway.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the significant efficacy of the Punica granatum in enhancing skin health, this research employed network pharmacology and in vivo studies to explore the P. granatum ethanolic leaf extract's (PGEL) mechanism in alleviating skin sclerosis. A model of skin fibrosis brought on by bleomycin (100 µl/rat, sc.) was adopted for experimental validation, where PGEL was orally administered at 200 and 400 mg/kg to rats for 3 weeks. Seventy-three compounds of PGEL were identified by LC/MS/MS belonging to different chemical classes; an organic acid, 12 phenolic acids, 4 polysaccharides, 3 amino acids, 19 gallic acid derivatives,7 ellagic acid derivatives, 14 flavonoides, three anthocyanins, 3 fatty acids and 7 miscellaneous groups. Five compounds (Catechin-3-O-gallate, 3,3'-di-O-methyl-4-O-(xylopyranosyl) ellagic acid, ellagic acid glucoside, valoneic acid dilactone, and vitexin 2-O-gallate) were isolated from the PGEL. Network pharmacological studies clarified that TNF-α, TGF-β1, Snail1, p-Smad3, MMP-9, IL-17 A, and COL1A1 are the core targets for skin fibrosis. PGEL lessened MPO and increased SOD activity in rat's skin, underscoring its antioxidant activity. Furthermore, the TNF-α, IL-17 A and MMP-9 were decreased in PGEL groups. Mechanistic studies revealed that PGEL exerts its anti-fibrotic action by downregulating the TGF-β1, Snail 1, COL1A1, and p-Smad 3 in the skin tissues. Additionally, histopathological analyses informed the decline in dermal alterations and thickness in rats treated with PGEL. Collectively, our results give clear evidence that PGEL work through multi-pathway modulation by targeting the core proteins of inflammation mediated the TGF-β/Snail1/Smad 3 signaling, thereby exerting a therapeutic action on skin fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.